The Anchor
Alnylam (ALNY) is the “Anchor” in Porter Stansberry’s Ignition Point pitch, and for once the label fits the company. This is the firm that turned RNA interference, the gene-silencing mechanism that won Andrew Fire and Craig Mello the 2006 Nobel Prize, into medicines patients actually take. Porter Stansberry, the founder of Porter & Co. and the name behind the long-running Stansberry newsletter family, frames Alnylam as the steady name in his biotech barbell, the one you hold while the smaller speculative picks swing for the fences.
There is real substance behind the positioning. Alnylam was founded in 2002, and it spent the next two decades solving the single hardest problem in the field: getting RNAi molecules into cells without them dissolving in the bloodstream first. That journey, not any one drug, is the story the pitch is really selling.
The 20-Year Delivery Problem
RNA interference sounds elegant on paper. A short strand of RNA slips into a cell, finds a matching messenger RNA, and silences the gene before it can churn out a harmful protein. The chemistry earned a Nobel Prize in 2006, and the medical potential was obvious from day one. The obstacle was always delivery. RNA is fragile. The immune system attacks foreign RNA on sight. And a large, negatively charged molecule does not cross a cell membrane by accident.
Alnylam spent roughly two decades on that problem. Early attempts stalled, investors lost patience, and a string of rival approaches failed outright. The company eventually landed on a chemistry that shields the RNA and delivers it selectively to the liver, the organ that produces many of the proteins behind rare and common diseases alike. That breakthrough is why Alnylam now sells commercial drugs such as Amvuttra instead of just promising a pipeline of interesting ideas.
This is the moat Porter Stansberry is really pointing at when he calls Alnylam the anchor. It is not a single product. It is twenty years of hard-won chemistry that a competitor cannot copy in a quarter. We walk through the mechanism from first principles in our RNA interference explainer.
The Tuschl II Patent Moat
The second leg of the moat is intellectual property. The Tuschl II patents, named for researcher Thomas Tuschl, cover foundational RNAi chemistry and delivery methods. Alnylam controls or licenses a meaningful slice of these patents, which means a large part of the industry pays Alnylam for the right to build RNAi drugs at all.
That detail matters because the field is no longer empty. Arrowhead Pharmaceuticals and Silence Therapeutics both work the same gene-silencing territory, each with its own chemistry and its own patent claims. But the foundational estate is a big part of why Alnylam sits in the anchor seat while those names take the challenger roles. The anchor collects the tollbooth; the challengers pay it.
Where It Fits in the Lp(a) Race
Alnylam is the anchor, not the Lp(a) pick, and that distinction is worth keeping straight. The Ignition Point pitch is built around gene silencing for lipoprotein(a), the genetically determined form of cholesterol that statins barely move and that raises cardiovascular risk when it runs high. Several of the drugs racing to lower Lp(a) are RNAi medicines, and some trace their chemistry back to the same delivery breakthroughs Alnylam pioneered.
Alnylam itself is not the name Porter Stansberry points to for Lp(a). That job goes to the smaller, more speculative picks in the barbell. But the platform economics still apply: when a whole field runs on RNAi, the company that owns the foundational chemistry and patents is positioned to collect from the winners, whoever they turn out to be. That is a genuinely attractive place to sit, and it is the strongest version of the anchor argument.
The Numbers and the Risks
The valuation is where the anchor story gets harder to defend. Alnylam trades near $246.51 with a market cap around $34 billion. On a forward basis it fetches roughly 23 times earnings, with per-share earnings expected to climb from about $9 in 2026 toward $15 by 2028. That is a premium multiple even for a profitable biotech.
The risk is simply the price of admission. Alnylam’s revenue story is real, but it is also maturing, and a lot of the delivery-platform success is already in the share price. A 23-times forward multiple leaves less cushion if growth disappoints, which cuts against the steady ballast role the pitch assigns it. The barbell only works when the anchor actually stays put, and the margin for error at this valuation is thinner than the tease suggests. We lay out the full framework in our best biotech stocks guide.
Ready to see the research? Click here to access Porter Stansberry’s report.
NewsletterVetter is an independent publication. We receive compensation from some of the services we review through affiliate links. Nothing on this site is investment advice. Always do your own research.